BMY
NYSEBRISTOL MYERS SQUIBB CO
Health Care, Pharmaceuticals
$64.72
close 7 Aug 2026
+40.91%
52-week change
$132.20B
market cap
$42.52
$68.10
52-week range
| Line item | TTM | FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | FY11 | FY10 | FY09 | FY08 | FY07 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income | ||||||||||||||||||||
| Revenue | $49.19B | $48.19B | $48.30B | $45.01B | $46.16B | $46.39B | $42.52B | $26.15B | $22.56B | $20.78B | $19.43B | $16.56B | $15.88B | $16.39B | $17.62B | $21.24B | $19.48B | $18.81B | $17.72B | $15.62B |
| Cost of revenue | $14.68B | $13.94B | $13.97B | $10.69B | $10.14B | $9.94B | $11.77B | $8.08B | $6.47B | $6.01B | $4.97B | $3.91B | $3.93B | $4.62B | $4.61B | $5.60B | $5.28B | $5.14B | $5.32B | $4.92B |
| Gross profit | — | — | — | — | — | — | $30.75B | $18.07B | $16.09B | $14.68B | $14.48B | $12.65B | $11.95B | $11.77B | $13.01B | $15.65B | $14.21B | $13.67B | — | — |
| R&D | $10.72B | $9.95B | $11.16B | $9.30B | $9.51B | $10.20B | $10.05B | $6.15B | $6.33B | $6.47B | $5.01B | $5.92B | $4.53B | $3.73B | $3.90B | $3.84B | $3.57B | $3.65B | $3.51B | $3.16B |
| SG&A | $7.41B | $7.27B | $8.41B | $7.77B | $7.81B | $7.69B | $7.66B | $4.87B | $4.55B | $4.75B | $4.98B | $4.84B | $4.82B | $4.94B | $4.22B | $4.20B | $3.69B | $3.95B | $4.14B | $3.94B |
| Operating income | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Interest expense | $1.73B | $1.89B | $1.95B | $1.17B | $1.23B | $1.33B | $1.42B | $656.00M | $183.00M | $196.00M | $167.00M | $184.00M | $203.00M | $199.00M | $182.00M | $145.00M | $145.00M | $184.00M | $310.00M | — |
| Tax expense | $2.63B | $2.27B | $554.00M | $400.00M | $1.37B | $1.08B | $2.12B | $1.52B | $1.02B | $4.16B | $1.41B | $446.00M | $352.00M | $311.00M | -$161.00M | $1.72B | $1.56B | $1.18B | $1.09B | $471.00M |
| Net income | $9.28B | $7.05B | -$8.95B | $8.03B | $6.33B | $6.99B | -$9.02B | $3.44B | $4.92B | $1.01B | $4.46B | $1.57B | $2.00B | $2.56B | $1.96B | $3.71B | $3.10B | $10.61B | $5.25B | $2.17B |
| Diluted EPS | $4.55 | $3.46 | -$4.41 | $3.86 | $2.95 | $3.12 | -$3.99 | $2.01 | $3.01 | $0.6100 | $2.65 | $0.9300 | $1.20 | $1.54 | $1.16 | $2.16 | $1.79 | $5.34 | $2.62 | $1.09 |
| Gross margin | — | — | — | — | — | — | 72.31% | 69.10% | 71.34% | 70.67% | 74.54% | 76.39% | 75.24% | 71.81% | 73.84% | 73.65% | 72.92% | 72.67% | — | — |
| Operating margin | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Net margin | 18.87% | 14.64% | -18.53% | 17.83% | 13.71% | 15.08% | -21.20% | 13.15% | 21.81% | 4.85% | 22.94% | 9.45% | 12.62% | 15.64% | 11.12% | 17.46% | 15.92% | 56.42% | 29.62% | 13.86% |
filed 30 Jul 2026